Mohammaditabar Mahdi, Forghani-Ramandi Mohammad-Moien, Amirani Niusha, Saidi Sofia, Zare Sama, Hafshejani Negin Fathi, Mozhgani Sayed-Hamidreza
Student Research Committee, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.
Department of Microbiology & Virology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.
BMC Nephrol. 2025 Jul 1;26(1):340. doi: 10.1186/s12882-025-04181-5.
The transmission of infectious agents through hemodialysis is one of this critical treatment's most significant side effects. Human T-lymphotropic virus 1 (HTLV-1) is an endemic oncogenic virus in Iran. Due to its relatively lower prevalence, the infection with this virus is not routinely screened for in patients before hemodialysis. In this study, we aimed to evaluate the seropositivity of HTLV-1 in hemodialysis-dependent patients of Iran to better understand how this treatment can help the virus spread.
A comprehensive systematic review and meta-analysis were performed by searching PubMed, Scopus, Google Scholar, and Web of Science databases for studies on the prevalence of HTLV-1 among hemodialysis-dependent patients. The meta-analysis was conducted using R.
Twelve studies were included. Overall, the prevalence of HTLV1 among patients dependent on hemodialysis treatment was 2.37% (I2 = 70.8% /p-value < 0.0001). The funnel plot asymmetry and trim and fill analysis results showed three studies with higher prevalence as outlier results which all were originated in endemic region of Iran, Khorasan. Highlighting the higher prevalence in the endemic areas.
Considering the significantly higher prevalence of infection with HTLV-1 in hemodialysis-dependent patients compared to the general population of Iran, more efforts seem necessary to prevent the transmission of the virus through this treatment, even considering screening protocols similar to blood transfusion protocols.
通过血液透析传播感染因子是这种关键治疗方法最显著的副作用之一。人类嗜T淋巴细胞病毒1型（HTLV-1）是伊朗的一种地方性致癌病毒。由于其患病率相对较低，在血液透析前患者中通常不会对这种病毒感染进行常规筛查。在本研究中，我们旨在评估伊朗依赖血液透析患者中HTLV-1的血清阳性率，以更好地了解这种治疗方式如何助长病毒传播。
通过检索PubMed、Scopus、谷歌学术和科学网数据库，对依赖血液透析患者中HTLV-1患病率的研究进行全面系统综述和荟萃分析。荟萃分析使用R软件进行。
纳入了12项研究。总体而言，依赖血液透析治疗患者中HTLV-1的患病率为2.37%（I2 = 70.8%/p值<0.0001）。漏斗图不对称性以及修剪和填充分析结果显示，有三项患病率较高的研究为异常值结果，所有这些研究均来自伊朗的地方性流行地区霍拉桑。突出了地方性流行地区较高的患病率。
考虑到依赖血液透析患者中HTLV-1感染的患病率显著高于伊朗普通人群，即使考虑采用类似于输血方案的筛查方案，似乎也需要做出更多努力来预防该病毒通过这种治疗方式传播。
